An investigation for investors in NASDAQ:STDY shares over potential securities laws violations by Steadymed Ltd was announced.
San Diego, CA -- (SBWIRE) -- 09/20/2017 -- Steadymed Ltd is under investigation over possible violations of securities laws. The investigation was announced on behalf of investors NASDAQ:STDY shares in connection with certain financial statements made by Steadymed Ltd.
Investors who purchased shares of Steadymed Ltd (NASDAQ:STDY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm focuses on whether a series of statements by Steadymed Ltd regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Israel based SteadyMed Ltd. is a specialty pharmaceutical company that is focused on the development and commercialization of various therapeutic product candidates.
On August 31, 2017, Steadymed Ltd announced receipt of a Refusal to File letter from the U.S. Food and Drug Administration ("FDA") concerning the Company's New Drug Application ("NDA") for Treyvent, a pulmonary arterial hypertension treatment. Based on a preliminary review of the NDA, which was submitted in June 2017, the FDA determined that the application is not sufficiently complete to permit a substantive review.
Those who purchased shares of Steadymed Ltd (NASDAQ:STDY) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com